Oorsprong van het eerstegraads netwerk van Matthew B. Francis
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Catena Biosciences, Inc.
Catena Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Catena Biosciences, Inc. is an American biotech company that was founded in May 2021. The company is based in El Cerrito, CA. The company is based on technology developed in the Doudna and Francis labs at the University of California, Berkeley. Catena Biosciences' patented technology, called the Catenase platform, allows the construction of biomolecules that are currently unobtainable using modern manufacturing techniques. The platform has applications across multiple therapeutic areas, with an initial focus in oncology. The company is the recipient of an NIH SBIR grant and the American Cancer Society's BrightEdge Golden Ticket at UC's Bakar Labs. The company was founded in 2020 by Marco Lobba, Gregorio Guillen, Matthew B. Francis. Marco Lobba has been the CEO since 2020.
4
| Holding Company | Miscellaneous Commercial Services | 4 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Matthew B. Francis via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
New York Blood Center, Inc.
New York Blood Center, Inc. Medical/Nursing ServicesHealth Services New York Blood Center, Inc. operates blood distribution and research organizations. It provides blood and blood products for transfusions annually. The company was founded in 1964 and is located in New York, NY. | Medical/Nursing Services | Private Equity Investor | |
Warwick Business School | College/University | Masters Business Admin | |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor | |
Boston University | College/University | Graduate Degree | |
College of Charleston | College/University | Undergraduate Degree | |
GLYCOMIMETICS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
CureDuchenne Ventures LLC
CureDuchenne Ventures LLC Investment ManagersFinance CureDuchenne Ventures LLC (CureDuchenne Ventures) is a venture capital subsidiary of CureDuchenne, founded in 2014 by Debra Miller. The firm is headquartered in Newport Beach, California. | Investment Managers | Private Equity Investor | |
Social Impact Capital, Inc.
Social Impact Capital, Inc. Investment ManagersFinance Social Impact Capital LLC (Social Impact) is a Venture Capital firm founded in 2015 by Sarah Cone. The firm is headquartered in New York. | Investment Managers | Private Equity Investor | |
Pioneer Fund/NY/
Pioneer Fund/NY/ Investment ManagersFinance Pioneer Fund/NY/ is a venture capital firm founded by Jason Gray. The firm is headquartered in San Francisco, California. | Investment Managers | Private Equity Investor | |
KaloCyte, Inc.
KaloCyte, Inc. BiotechnologyHealth Technology Kalocyte, Inc. operates as a pre-clinical stage healthcare biotech company. It provides artificial red blood cell substitutes used for trauma care related services. The company was founded in 2016 and is headquartered in Baltimore, MD. | Biotechnology | Director/Board Member | |
Aronora, Inc.
Aronora, Inc. Pharmaceuticals: MajorHealth Technology Aronora, Inc. operates as an early clinical stage translational biopharmaceutical company. It researches and develops proprietary biological therapeutics. The company was founded by Andras Gruber and Erik I. Tucker and is headquartered in Portland, OR. | Pharmaceuticals: Major | Director/Board Member | |
Rarebase, PBC
Rarebase, PBC Packaged SoftwareTechnology Services Rarebase, PBC is a biotech company that is dedicated to discovering and developing medicines for rare diseases. The company is based in Palo Alto, CA and was founded by Onno Faber and Omid Karkouti. The company has a product engine that is designed to discover treatments for hundreds of monogenic diseases simultaneously. Rarebase has already uncovered potential treatments for hundreds of rare diseases and has built a "drug-gene atlas" to enable AI-driven drug discovery. Onno Faber has been the CEO since incorporation. | Packaged Software | Consultant / Advisor | |
Thymmune Therapeutics
Thymmune Therapeutics BiotechnologyHealth Technology Thymmune Therapeutics is a preclinical biotechnology company located in the US that is developing a machine learning-enabled thymic cell engineering platform to restore normal immune function in aging and disease. The American company's approach in ipsc-thymic cell manufacturing can generate off-the-shelf cells at scale. Thymmune is developing a pipeline of therapies to treat immunodeficiencies, transplant-related, and autoimmune diseases. The company has strong IP positioning and is backed by early investors and founders of successful high-profile biotechnology companies. | Biotechnology | Director/Board Member | |
Cellurx | Chief Executive Officer | ||
Nybc Ventures
Nybc Ventures Investment ManagersFinance NYBC Ventures (NYBC Ventures) is a venture capital subsidiary of New York Blood Center Inc founded in 2022. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor | |
Ravenshaw University | College/University | Undergraduate Degree |
Statistieken
Internationaal
Verenigde Staten | 15 |
Verenigd Koninkrijk | 2 |
India | 2 |
Sectoraal
Finance | 6 |
Consumer Services | 5 |
Health Technology | 5 |
Health Services | 2 |
Technology Services | 2 |
Operationeel
Director/Board Member | 7 |
Private Equity Investor | 6 |
Founder | 3 |
Chief Executive Officer | 2 |
Undergraduate Degree | 2 |
Sterkste connecties
Insiders | |
---|---|
Meg Wood | 11 |
Chinmaya Rath | 6 |
Marco Lobba | 2 |
Gregorio Guillen | 1 |
- Beurs
- Insiders
- Matthew B. Francis
- Bedrijfsconnecties